(Q30421625)

21 June 2017

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein (English)

1 reference

21 June 2017

1 reference

1 reference

Oscar Belda

1

1 reference

PubMed ID

23009750

21 June 2017

Paul Targett-Adams

series ordinal

2

1 reference

21 June 2017

23 September 2012

1 reference

21 June 2017

1 reference

21 June 2017

170

1 reference

21 June 2017

1-2

1 reference

21 June 2017

1-14

1 reference

Natural history of hepatitis C.

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

From structure to function: new insights into hepatitis C virus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C virus replication cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Assembly of infectious hepatitis C virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Drugs for hepatitis C: unlocking a new mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Efficient initiation of HCV RNA replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Diagnosis, management, and treatment of hepatitis C: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

A perspective on modelling hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The domain 2 of the HCV NS5A protein is intrinsically unstructured

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Telaprevir for previously untreated chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C virus: assembly and release of virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

In-cell click labelling of small molecules to determine subcellular localisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The global burden of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Identification of Hepatitis C Virus NS5A Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Correlation between NS5A dimerization and hepatitis C virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The C Terminus of Hepatitis C Virus NS4A Encodes an Electrostatic Switch That Regulates NS5A Hyperphosphorylation and Viral Replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Preliminary study of two antiviral agents for hepatitis C genotype 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Topology of the Membrane-Associated Hepatitis C Virus Protein NS4B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Interaction of Hepatitis C Virus Nonstructural Protein 5A with Core Protein Is Critical for the Production of Infectious Virus Particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Genotyping of hepatitis C virus: coinfection by multiple genotypes detected in children with chronic posttransfusion hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The lipid droplet is an important organelle for hepatitis C virus production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

New antiviral agents for hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Structural biology of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Boceprevir for untreated chronic HCV genotype 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Quantitative Analysis of the Hepatitis C Virus Replication Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The Isoform of Protein Kinase CKI Is Responsible for Hepatitis C Virus NS5A Hyperphosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Participation of Rab5, an Early Endosome Protein, in Hepatitis C Virus RNA Replication Machinery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Hepatitis C therapeutics: current status and emerging strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Visualization of Double-Stranded RNA in Cells Supporting Hepatitis C Virus RNA Replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The NS5A protein of hepatitis C virus is a zinc metalloprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Global burden of disease (GBD) for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Characteristics of patients with chronic infection due to hepatitis C virus of mixed subtype: prevalence, viral RNA concentrations, and response to interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

Palmitoylation and Polymerization of Hepatitis C Virus NS4B Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2012.09.007

10.1016/J.VIRUSRES.2012.09.007

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

23009750